Skip to content

Evolution and Risk Factors Associated With Geographic Atrophy Progression

Characterization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01694095
Acronym
GAIN
Enrollment
96
Registered
2012-09-26
Start date
2009-12-31
Completion date
2013-08-31
Last updated
2015-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geographic Atrophy

Keywords

Geographic atrophy, prognosis, risk factors, natural history

Brief summary

Age-related macular degeneration is one of the leading causes of blindness worldwide. The factors that induce the progression of geographic atrophy, the advanced form of dry age-related macular degeneration, remain poorly understood. The aims of this study are to describe the natural history of geographic atrophy and identify potential risk factors associated with a faster spread of atrophy that may be used to develop rational therapies.

Detailed description

Age-related macular degeneration is the leading cause of blindness in developed countries. Geographic atrophy is the advanced form of dry age-related macular degeneration, and currently has no effective therapy. Little is known about the risk factors that drive the progression of geographic atrophy, and yet they are crucial to understand the mechanisms of the disease. Therefore, the identification of risk factors associated with a faster spread of atrophy may help contribute to identify the causes of the disease and, ultimately, to develop new therapeutic strategies to manage the disorder. The current prospective, observational, natural history study has the following objectives: * Describe the natural history of geographic atrophy in anatomic and visual terms * Identify risk factors associated with a faster enlargement of atrophy The main hypothesis is that lipofuscin accumulation at the borders of atrophy as seen with fundus autofluorescence imaging is associated with a faster progression of the disease.

Interventions

None listed

Sponsors

Institut de la Macula y la Retina
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Both sexes * 50 years of age or older * Uni or bilateral areas of geographic atrophy in the macula (as defined as areas devoid of retinal pigment epithelium measuring at least 0.5 disk areas on a 35º fundus photograph centered on field 2) secondary to age-related macular degeneration * Willing to provide Informed consent

Exclusion criteria

* Other causes of geographic atrophy aside from age-related macular degeneration (ie, drug induced, central serous chorioretinopathy) * Prior history of wet age-related macular degeneration * Other significant concomitant macular diseases (ie, significant epiretinal membrane, stage II-IV macular hole) * Previous treatment with macular laser photocoagulation, photodynamic therapy, antiangiogenic drugs or other treatments for wet age-related macular degeneration * Intraocular surgery aside from phacoemulsification * Inability to measure the full extent of the area of atrophy on a 35º fundus autofluorescence image centered on field 2 * Areas of geographic atrophy in direct contact with peripapillary areas of atrophy

Design outcomes

Primary

MeasureTime frameDescription
Median/mean change in area of geographic atrophy as measured in mm2 with fundus autofluorescence on a 30º image centered on field 2From baseline to last follow-upFor measures related to change in the area of atrophy, a multivariable model will be fit and will include as an independent variable (amongst other presumed risk factors) fundus autofluorescence patterns

Secondary

MeasureTime frameDescription
Median change in area of geographic atrophy as measured in square root of mm2 with fundus autofluorescence on a 30º image centered on field 2From baseline to last follow-upExploratory analysis, either in the main publication or in another paper

Other

MeasureTime frameDescription
Median/mean change in best-corrected visual acuity as measured with an Early Treatment Diabetic Retinopathy Study chartFrom baseline to last follow-up
Percentage of eyes developing new choroidal neovascularization in the study eye as evaluated with fluorescein angiography and spectral-domain optical coherence tomographyFrom baseline to last follow-up
Median/mean change in area of geographic atrophy as measured in mm2 with fundus autofluorescence on a 30º image centered on field 2From baseline to last follow-upPrincipal component analysis will be used to reduce the number of independent variables to increase, if possible, the power of the study to detect an association

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026